PDCD1 and glioblastoma: A phase II trial of pembrolizumab, an anti‐PD1 checkpoint inhibitor, demonstrated increased survival in recurrent GBM patients treated with neoadjuvant pembrolizumab administration prior to surgery and post‐surgery adjuvant treatment.